Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application

TOKYO, July 6, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, " Astellas " ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company ' s Biologics...

https://www.drugs.com/nda/zolbetuximab_230706.html

Source: Drugs.com - New Drug Applications - July 6, 2023 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Grants | New Drug Applications | Pharmaceuticals